Evidence map›Paper›PMID 38133150›Full record

ArticleCancer medicine2024

Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon.

Mariam Zahwe, Aya El Sammak, Karim Ataya, Christelle Jabbour, Ayman Bsat, Bassel Hafez, Christine Atallah, Mira Kheil, Mohamad Ali Maktabi, Bashar Hassan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Mariam ZahweFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Aya El SammakFaculty of Health Sciences, American University of Beirut, Beirut, Lebanon.
Karim AtayaDepartment of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Christelle JabbourFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Ayman BsatDepartment of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Bassel HafezDepartment of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Christine AtallahFaculty of Medicine, University of Balamand, Beirut, Lebanon.
Mira KheilFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Mohamad Ali MaktabiFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Bashar HassanFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Vahe PanossianFaculty of Medicine, American University of Beirut, Beirut, Lebanon.
Hazem AssiDepartment of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-8483-0938
Jaber AbbasDepartment of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Eman SbaityDepartment of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0003-2969-4782
American University of Beirut · LBAmerican University of Beirut Medical Center · LBUniversity of Balamand · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in initially node-positive patients is still controversial. We aim to evaluate the oncologic outcomes of SLNB after NACT and further compare the results between those who were initially node-negative and node-positive.

methodsThis is a retrospective cohort that included patients diagnosed with invasive breast cancer and had surgical management between January 2010 and December 2016. Survival and recurrence data after 3-5 years were collected from patients' records. We divided patients into Group A who were initially node-negative and had SLNB ± axillary lymph node dissection (ALND) and Group B who were node-positive and had SLNB ± ALND.

resultsAmong initially node-negative patients, 43 out of 63 patients did SLNB (Group A). However, among initially node-positive patients only 28 out of 123 patients did SLNB (Group B). Out of the 71 patients who did SLNB after NACT, 26 patients had positive SLNs with only 14 patients who further underwent ALND. The identification rate of SLNB was 100% in Group A and 96.4% in Group B. The survival curves by nodal status showed no significant difference between overall survival and recurrence-free survival at 5 years between patients in Group A versus Group.

conclusionThe results suggest that in properly selected patients, SLNB can be feasible after NACT. Our results resemble the reported literature on accuracy of SLNB after NACT and adds to the growing pool of data on this topic.

Indexed as

Breast NeoplasmsNeoadjuvant TherapySentinel Lymph Node BiopsyTertiary Care CentersAdultAgedAxillaChemotherapy, AdjuvantFemaleHumansLebanonLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoplasm Recurrence, LocalRetrospective Studiesbreast cancerneoadjuvant therapysentinel lymph node biopsy

Identifiers

PMID38133150
PMCPMC10807658
OpenAlexW4390114513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.